More about Suven Pharmaceuticals Limited
Fundamentals for Suven Pharmaceuticals Limited
Regulatory Filings for Suven Pharmaceuticals Limited
Apollo FY26: When Healthcare Becomes a Flywheel
NITI Blueprint Could Turn Brain Drain Into $135Bn Engine
RAINMUMBAI Turns Rain Into a Financial Asset
India’s IT Sector Faces a Historic Breaking Point
Fundamentals for Suven Pharmaceuticals Limited
Business Operations:
Sector: HealthcareIndustry: Drug Manufacturers - Specialty & Generic
Suven Pharmaceuticals Limited operates as a bio-pharmaceutical company in India, the United States, Europe, and internationally. It develops, manufactures, and sells new chemical entity-based intermediates, active pharmaceutical ingredients, specialty chemicals, and formulated drugs under contract research and manufacturing services for pharmaceutical, biotechnology, and chemical companies. The company was founded in 1989 and is based in Hyderabad, India. Suven Pharmaceuticals Limited is a subsidiary of Berhyanda Limited.
Revenue projections:
SUVENPHAR's revenue is forecasted to dip below last year's figures, raising concerns for investors who are typically wary of declining financial performance. Such drops can directly affect the company's bottom line, potentially leading to a decrease in overall profitability, making investors more cautious in their decisions.
Financial Ratios:
| currentRatio | 0.0 |
|---|---|
| forwardPE | 0.0 |
| debtToEquity | 0.0 |
| earningsGrowth | 0.0 |
| revenueGrowth | 0.0 |
| grossMargins | 0.0 |
| operatingMargins | 0.0 |
| trailingEps | 0.0 |
| forwardEps | 0.0 |
Price projections:
SUVENPHAR's present price, in relation to projections, does not offer clear risks or opportunities. This stable scenario suggests a period of consolidation, where investors might prefer to hold off on significant changes in strategy.
Recommendation changes over time:
Analysts have maintained a buy bias for Suven Pharmaceuticals Limited, which could prompt investors to consider the stock as a viable investment. With this positive outlook, Suven Pharmaceuticals Limited is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.
If you have enjoyed reading, spread the word:
Good prospects:
Companies with the best and the worst fundamentals.
Latest Regulatory Filings for NSE500
Companies with the best and the worst technicals.
How Independent Directors Failed Rs 2,500 Crore in Value
India’s Stock Market May Be Sitting on a Trap